Terms ending in 2042
Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,404,500 | Homing Endonuclease Variants In force · High confidence | Novo Nordisk A/S | In force | High confidence | |
| US 12,297,451 | Cell Culture Medium In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,247,084 | Anti-Bcma Car Antibodies, Conjugates, and Methods of Use In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 12,291,560 | Dimerizing Agent Regulated Immunoreceptor Complexes In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,344,654 | Mage A4 T Cell Receptors In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,454,580 | FRB Antibodies In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.